Hugo Albrecht

Dr Hugo Albrecht

Senior Lecturer, Pharmaceutical Science

School of Pharmacy and Biomedical Science

College of Health

Hugo Albrecht is a senior lecturer at the University of South Australia conducting research and teaching activities within the Academic Unit of Clinical & Health Sciences. After obtaining his PhD at the Ludwig Institute for Cancer Research, Lausanne Branch, Switzerland, he has gained considerable experience in both commercial and academic settings in Europe and the US. He has focused his research efforts in the fields of cancer, immunology and neuroscience. For over 20 years, Hugo has been dedicated to preclinical pharmaceutical development. He has led over 20 major drug discovery projects while working in industry and academia. Hugo’s current focus is on the development of biochemical and cell-based assay systems, and animal models to identify and test pharmacologically active compounds. Of current interest is the discovery of novel kinase inhibitors for cancer treatment. In line with this he is leading the design of functional nanoparticles for targeted delivery of drugs into tumour cells.

Year Citation
2025 Li, K. L., Hickey, S. M., Albrecht, H., Logan, J. M., Lazniewska, J., Moore, C. R., . . . Brooks, D. A. (2025). Targeting prostate cancer cells using anti-sortilin and anti-syndecan-1 antibody drug conjugates. International Journal Of Molecular Sciences, 26(22, article no. 11145), 25 pages.
DOI
2025 Arafat, M., Wignall, A., Brewer, K., Song, Y., Albrecht, H., Prestidge, C. A., . . . Blencowe, A. (2025). Comparison of polymer-coated, drug-eluting self-expandable metal stents for the potential treatment of gastrointestinal cancers. Rsc Pharmaceutics, 2(3), 611-623.
DOI
2025 Dharmayanti, C., Clulow, A. J., Hussain, M. S., Gillam, T. A., Klingler Hoffmann, M., Albrecht, H., & Blencowe, A. (2025). Influence of pendant pyridyl regioisomers on the pH-responsive behaviour of polymer-homopeptide copolymers and micelles. European Polymer Journal, 234(113931), 1-11.
DOI Scopus1 WoS1
2025 Khetan, R., Lokman, N. A., Eldi, P., Price, Z. K., Oehler, M. K., Brooks, D. A., . . . Albrecht, H. (2025). Protease-Activated Receptor F2R Is a Potential Target for New Diagnostic/Prognostic and Treatment Applications for Patients with Ovarian Cancer. International Journal of Molecular Sciences, 26(17), 8529.
DOI
2024 Rajapaksha, W., Khetan, R., Johnson, I. R. D., Blencowe, A., Garg, S., Albrecht, H., & Gillam, T. A. (2024). Future theranostic strategies: emerging ovarian cancer biomarkers to bridge the gap between diagnosis and treatment. Frontiers in Drug Delivery, 4(1339936), 19 pages.
DOI Scopus10 WoS7 Europe PMC2
2024 Dharmayanti, C., Clulow, A. J., Gillam, T. A., Klingler Hoffmann, M., Albrecht, H., & Blencowe, A. (2024). Position matters: pyridine regioisomers influence secondary structure and micelle morphology in polymer-homopolypeptide micelles. Biomacromolecules, 25(7), 4095-4109.
DOI Scopus5 WoS5 Europe PMC2
2024 Khetan, R., Eldi, P., Lokman, N. A., Ricciardelli, C., Oehler, M. K., Blencowe, A., . . . Albrecht, H. (2024). Unveiling G-protein coupled receptors as potential targets for ovarian cancer nanomedicines: from RNA sequencing data analysis to in vitro validation.. J Ovarian Res, 17(1), 156.
DOI Scopus2 WoS2 Europe PMC2
2024 Saddam Hussain, M., Khetan, R., Albrecht, H., Krasowska, M., & Blencowe, A. (2024). Oligoelectrolyte-mediated, pH-triggered release of hydrophobic drugs from non-responsive micelles: Influence of oligo(2-vinyl pyridine)-loading on drug-loading, release and cytotoxicity. International Journal of Pharmaceutics, 661(124368), 15 pages.
DOI Scopus5 WoS3 Europe PMC1
2024 Oehler, J. B., Rajapaksha, W., & Albrecht, H. (2024). Emerging Applications of Nanoparticles in the Diagnosis and Treatment of Breast Cancer. Journal of Personalized Medicine, 14(7), 18 pages.
DOI Scopus35 WoS25 Europe PMC13
2023 Hussain, M. S., Faisal, K. S., Clulow, A. J., Albrecht, H., Krasowska, M., & Blencowe, A. (2023). Influence of Lyophilization and Cryoprotection on the Stability and Morphology of Drug-Loaded Poly(ethylene glycol-b-ε-caprolactone) Micelles. Polymers, 15(8), 15 pages.
DOI Scopus8 WoS6 Europe PMC6
2023 Saddam Hussain, M., Khetan, R., Clulow, A. J., Ganesan, R., MacMillan, A., Robinson, N., . . . Blencowe, A. (2023). Teaching an Old Dog New Tricks: A Global Approach to Enhancing the Cytotoxicity of Drug-Loaded, Non-responsive Micelles Using Oligoelectrolytes. ACS Applied Materials and Interfaces, 16(8), 9736-9748.
DOI Scopus4 WoS4 Europe PMC2
2022 Anshabo, A. T., Bantie, L., Diab, S., Lenjisa, J., Kebede, A., Long, Y., . . . Wang, S. (2022). An Orally Bioavailable and Highly Efficacious Inhibitor of CDK9/FLT3 for the Treatment of Acute Myeloid Leukemia. Cancers, 14(5), 1113.
DOI Scopus12 WoS10 Europe PMC10
2022 Khetan, R., Dharmayanti, C., Gillam, T. A., Kübler, E., Klingler-Hoffmann, M., Ricciardelli, C., . . . Albrecht, H. (2022). Using GPCRs as Molecular Beacons to Target Ovarian Cancer with Nanomedicines. Cancers, 14(10), 1-32.
DOI Scopus12 WoS12 Europe PMC11
2022 Teo, T., Kasirzadeh, S., Albrecht, H., Sykes, M. J., Yang, Y., & Wang, S. (2022). An overview of CDK3 in cancer: clinical significance and pharmacological implications. Pharmacological Research, 180, 16 pages.
DOI Scopus12 WoS11 Europe PMC11
2021 Anshabo, A. T., Milne, R., Wang, S., & Albrecht, H. (2021). CDK9: A comprehensive review of its biology, and its role as a potential target for anti-cancer agents. Frontiers in Oncology, 11(678559), 1-24.
DOI Scopus110 WoS106 Europe PMC98
2021 Dharmayanti, C., Gillam, T. A., Klingler Hoffmann, M., Albrecht, H., & Blencowe, A. (2021). Strategies for the development of pH-responsive synthetic polypeptides and polymer-peptide hybrids: recent advancements. Polymers, 13(4), 1-16.
DOI Scopus47 WoS37 Europe PMC20
2021 Bantie, L., Tadesse, S., Likisa, J., Yu, M., Noll, B., Heinemann, G., . . . Wang, S. (2021). Erratum to “A first-in-class CDK4 inhibitor demonstrates in vitro, ex-vivo and in vivo efficacy against ovarian cancer” (Gynecologic Oncology (2020) 159(3) (827–838), (S0090825820339056), (10.1016/j.ygyno.2020.09.012)). Gynecologic Oncology, 163(1), 215.
DOI
2021 Arafat, M., Song, Y., Brewer, K., Fouladian, P., Parikh, A., Albrecht, H., . . . Garg, S. (2021). Pharmaceutical development of 5-fluorouracil- eluting stents for the potential treatment of gastrointestinal cancers and related obstructions. Drug Design Development and Therapy, 15, 1495-1507.
DOI Scopus8 WoS9 Europe PMC5
2021 Arafat, M., Fouladian, P., Wignall, A., Song, Y., Parikh, A., Albrecht, H., . . . Blencowe, A. (2021). Development and in vitro evaluation of 5-fluorouracil-eluting stents for the treatment of colorectal cancer and cancer-related obstruction. Pharmaceutics, 13(1), 1-22.
DOI Scopus23 WoS20 Europe PMC11
2020 Bantie, L., Tadesse, S., Likisa, J., Yu, M., Noll, B., Heinemann, G., . . . Wang, S. (2020). A first-in-class CDK4 inhibitor demonstrates in vitro, ex-vivo and in vivo efficacy against ovarian cancer.. Gynecol Oncol, 159(3), 827-838.
DOI Scopus16 WoS18 Europe PMC16
2019 Khair, N. Z., Lenjisa, J. L., Tadesse, S., Kumarasiri, M., Basnet, S. K. C., Mekonnen, L. B., . . . Wang, S. (2019). Discovery of CDK5 inhibitors through structure-guided approach. ACS, 10(5), 786-791.
DOI Scopus23 WoS21 Europe PMC18
2019 Arafat, M., Fouladian, P., Blencowe, A., Albrecht, H., Song, Y., & Garg, S. (2019). Drug-eluting non-vascular stents for localised drug targeting in obstructive gastrointestinal cancers. Journal of Controlled Release, 308, 209-231.
DOI Scopus31 WoS27 Europe PMC17
2019 Abdelaziz, A. M., Diab, S., Islam, S., KC Basnet, S., Noll, B., Li, P., . . . Wang, S. (2019). Discovery of n-phenyl-4-(1h-pyrrol-3-yl)pyrimidin-2-amine derivatives as potent mnk2 inhibitors: design, synthesis, sar analysis, and evaluation of in vitro anti-leukaemic activity. Medicinal chemistry, 15(6), 600-621.
DOI Scopus6 WoS5 Europe PMC5
2019 Abdelaziz, A. M., Basnet, S. K. C., Islam, S., Li, M., Tadesse, S., Albrecht, H., . . . Wang, S. (2019). Synthesis and evaluation of 2'H-spiro[cyclohexane-1,3'-imidazo[1,5-a]pyridine]-1',5'-dione derivatives as Mnk inhibitors. Bioorganic & medicinal chemistry letters, 29(18), 2650-2654.
DOI Scopus10 WoS10 Europe PMC7
2019 Albrecht, H., & Kübler, E. (2019). Systematic meta-analysis identifies co-expressed kinases and gpcrs in ovarian cancer tissues revealing a potential for targeted kinase inhibitor delivery. Pharmaceutics, 11(9), 17 pages.
DOI Scopus7 WoS7 Europe PMC5
2018 Kübler, E., & Albrecht, H. (2018). Large set data mining reveals overexpressed GPCRs in prostate and breast cancer: potential for active targeting with engineered anti-cancer nanomedicines. Oncotarget, 9(38), 24882-24897.
DOI Scopus29 Europe PMC22
2018 Zhang, W., Song, Y., Eldi, P., Guo, X., Hayball, J., Garg, S., & Albrecht, H. (2018). Targeting prostate cancer cells with hybrid elastin-like polypeptide/liposome nanoparticles. International Journal of Nanomedicine, 13, 293-305.
DOI Scopus47 WoS36 Europe PMC24
2017 Tadesse, S., Yu, M., Mekonnen, L. B., Lam, F., Islam, S., Tomusange, K., . . . Wang, S. (2017). Highly potent, selective, and orally bioavailable 4-Thiazol-N-(pyridin-2-yl)pyrimidin-2-amine cyclin-dependent kinases 4 and 6 inhibitors as anticancer drug candidates: design, synthesis, and evaluation. Journal of medicinal chemistry, 60(5), 1892-1915.
DOI Scopus72 WoS65 Europe PMC40
2017 Kumarasiri, M., Teo, T., Yu, M., Philip, S., Basnet, S. K. C., Albrecht, H., . . . Wang, S. (2017). In search of novel CDK8 inhibitors by virtual screening. Journal of chemical information and modeling, 57(3), 413-416.
DOI Scopus15 WoS16 Europe PMC10
2017 Diab, S., Abdelaziz, A. M., Li, P., Teo, T., Basnet, S. K. C., Noll, B., . . . Wang, S. (2017). Dual inhibition of Mnk2 and FLT3 for potential treatment of acute myeloid leukaemia. European journal of medicinal chemistry, 139, 762-772.
DOI Scopus23 WoS22 Europe PMC19
2017 Lenjisa, J. L., Tadesse, S., Khair, N. Z., Kumarasiri, M., Yu, M., Albrecht, H., . . . Wang, S. (2017). CDK5 in oncology: recent advances and future prospects.. Future medicinal chemistry, 9(16), 1939-1962.
DOI Scopus36 WoS35 Europe PMC32
2016 Rahaman, M. H., Kumarasiri, M., Mekonnen, L. B., Yu, M., Diab, S., Albrecht, H., . . . Wang, S. (2016). Targeting CDK9: A promising therapeutic opportunity in prostate cancer. Endocrine Related Cancer, 23(12), T211-T226.
DOI Scopus63 WoS58 Europe PMC53
2016 Diab, S., Li, P., Basnet, S. K. C., Lu, J., Yu, M., Albrecht, H., . . . Wang, S. (2016). Unveiling new chemical scaffolds as Mnk inhibitors. Future Medicinal Chemistry, 8(3), 271-285.
DOI Scopus22 WoS20 Europe PMC15
2016 Li, P., Diab, S., Yu, M., Adams, J., Islam, S., Basnet, S. K. C., . . . Wang, S. (2016). Inhibition of Mnk enhances apoptotic activity of cytarabine in acute myeloid leukemia cells. Oncotarget, 7(35), 1-15.
DOI Scopus23 WoS23 Europe PMC22
2016 Zhang, W., Garg, S., Eldi, P., Zhou, F., Johnson, I., Brooks, D., . . . Albrecht, H. (2016). Targeting prostate cancer cells with genetically engineered polypeptide-based micelles displaying gastrin-releasing peptide. International Journal of Pharmaceutics, 513(1-2), 270-279.
DOI Scopus27 WoS25 Europe PMC17
2015 Yu, M., Li, P., K c Basnet, S., Kumarasiri, M., Diab, S., Teo, T., . . . Wang, S. (2015). Discovery of 4-(dihydropyridinon-3-yl)amino-5-methylthieno[2,3-d[pyrimidine derivatives as potent Mnk inhibitors: Synthesis, structure-activity relationship analysis and biological evaluation. European Journal of Medicinal Chemistry, 95, 116-126.
DOI Scopus37 WoS37 Europe PMC20
2015 Teo, T., Lam, F., Yu, M., Yang, Y., Basnet, S., Albrecht, H., . . . Wang, S. (2015). Pharmacologic inhibition of MNKs in acute myeloid leukemia. Molecular Pharmacology, 88(2), 380-389.
DOI Scopus31 WoS28 Europe PMC23
2015 Teo, T., Yang, Y., Yu, M., Basnet, S., Gillam, T., Hou, J., . . . Wang, S. (2015). An integrated approach for discovery of highly potent and selective Mnk inhibitors: Screening, synthesis and SAR analysis. European Journal of Medicinal Chemistry, 103, 539-550.
DOI Scopus31 WoS27 Europe PMC17
2015 Basnet, S., Diab, S., Schmid, R., Yu, M., Yang, Y., Gillam, T., . . . Wang, S. (2015). Identification of a highly conserved allosteric binding site on Mnk1 and Mnk2 s. Molecular Pharmacology, 88(5), 935-948.
DOI Scopus15 WoS15 Europe PMC10
2014 Diab, S., Teo, T. H. S., Kumarasiri, M., Li, P., Yu, M., Lam, F., . . . Wang, S. (2014). Discovery of 5-(2-(phenylamino)pyrimidin-4-yl)thiazol-2(3H)-one derivatives as potent Mnk2 inhibitors : synthesis, SAR analysis and biological evaluation. ChemMedChem, 9(5), 962-972.
DOI Scopus80 WoS76 Europe PMC58
2008 Joesch, C., Guevarra, E., Parel, S. P., Bergner, A., Zbinden, P., Konrad, D., & Albrecht, H. (2008). Use of FLIPR membrane potential dyes for validation of high-throughput screening with the FLIPR and µARCS technologies : identification of ion channel modulators acting on the GABAA receptor. Journal of biomolecular screening, 13(3), 218-228.
DOI Scopus42 WoS37 Europe PMC33
2007 Scarsi, M., Podvinec, M., Roth, A., Hug, H., Kersten, S., Albrecht, H., . . . Rücker, C. (2007). Sulfonylureas and glinides exhibit peroxisome proliferator-activated receptor γ activity: A combined virtual screening and biological assay approach. Molecular Pharmacology, 71(2), 398-406.
DOI Scopus53 WoS43 Europe PMC30
2004 Kvajo, M., Albrecht, H., Meins, M., Hengst, U., Troncoso, E., Lefort, S., . . . Monard, D. (2004). Regulation of brain proteolytic activity is necessary for the in vivo function of NMDA receptors. Journal of Neuroscience, 24(43), 9734-9743.
DOI Scopus48 WoS44 Europe PMC41
2002 Salter, J. P., Choe, Y., Albrecht, H., Franklin, C., Lim, K. C., Craik, C. S., & McKerrow, J. H. (2002). Cercarial elastase is encoded by a functionally conserved gene family across multiple species of schistosomes. Journal of Biological Chemistry, 277(27), 24618-24624.
DOI Scopus85 WoS83 Europe PMC74
2001 Hengst, U., Albrecht, H., Hess, D., & Monard, D. (2001). The phosphatidylethanolamine-binding protein is the prototype of a novel family of serine protease inhibitors. Journal of Biological Chemistry, 276(1), 535-540.
DOI Scopus167 WoS163 Europe PMC143
1995 Carrel, S., Hartmann, F., Salvi, S., Albrecht, H., Schreyer, M., & Rimoldi, D. (1995). Expression of type a and b tumor necrosis factor (TNF) receptors on melanoma cells can be regulated by dbc‐AMP and IFN‐γ. International Journal of Cancer, 62(1), 76-83.
DOI Scopus16 WoS14 Europe PMC14
1995 Albrecht, H., Schook, L. B., & Jongeneel, C. V. (1995). Nuclear migration of NF-κB correlates with TNF-α mRNA accumulation. Journal of Inflammation, 45(1), 64-71.
Scopus31 WoS29 Europe PMC15
1995 Heumann, D., Gallay, P., Barras, C., Albrecht, H., de Flaugergues, J. C., Steck, A., & Glauser, M. P. (1995). Lipopolysaccharide binding protein (LBP) as a marker of protein leakage in cerebrospinal fluid. Journal of Endotoxin Research, 2(1), 1-7.
DOI Scopus5
1994 Schook, L. B., Albrecht, H., Gallay, P., & Jongeneel, C. V. (1994). Cytokine regulation of TNF-α mRNA and protein production by unprimed macrophages from C57BI/6 and NZW mice. Journal of Leukocyte Biology, 56(4), 514-520.
DOI Scopus20 WoS23 Europe PMC14
1994 Albrecht, H., Tschopp, J., & Jongeneel, C. V. (1994). Bcl-2 protects from oxidative damage and apoptotic cell death without interfering with activation of NF-κB by TNF. FEBS Letters, 351(1), 45-48.
DOI Scopus99 WoS96 Europe PMC74
1992 Albrecht, H., Shakhov, A. N., & Jongeneel, C. V. (1992). trans activation of the tumor necrosis factor alpha promoter by the human T-cell leukemia virus type I tax1 protein. Journal of Virology, 66(10), 6191-6193.
DOI Scopus42 WoS45 Europe PMC31
1991 BABST, M., ALBRECHT, H., WEGMANN, I., BRUNISHOLZ, R., & ZUBER, H. (1991). Single amino acid substitutions in the B870 α and β light‐harvesting polypeptides of Rhodobacter capsulatus Structural and spectral effects. European Journal of Biochemistry, 202(2), 277-284.
DOI Scopus22 WoS23 Europe PMC14

Year Citation
2025 Khetan, R., Eldi, P., Lokman, N., Ricciardelli, C., Oehler, M., Blencowe, A., . . . Albrecht, H. (2025). Leveraging GPCR overexpression for personalized nanomedicine: A novel approach in ovarian cancer therapy. In CANCER RESEARCH Vol. 85 (pp. 2 pages). IL, Chicago: AMER ASSOC CANCER RESEARCH.
DOI
2025 Khetan, R., Lokman, N. A., Eldi, P., Price, Z. K., Oehler, M. K., Brooks, D. A., . . . Albrecht, H. (2025). Protease-activated receptor F2R/PAR1 is a potential target for new diagnostic/prognostic and treatment applications for patients with ovarian cancer. In CANCER RESEARCH Vol. 85 (pp. A36). AMER ASSOC CANCER RESEARCH.
DOI
2019 Rahaman, M. H., Zhang, Y., Islam, M. S., Heinemann, G., Anshabo, A. T., Albrecht, H., . . . Wang, S. (2019). LS007, a potent and orally bioavailable CDK9 inhibitor, suppresses the growth of triple-negative and estrogen receptor-positive breast cancer. In CANCER RESEARCH Vol. 79 (pp. 2 pages). GA, Atlanta: AMER ASSOC CANCER RESEARCH.
DOI
2004 Albrecht, H., Zbinden, P., Rizzi, A., Villetti, G., Riccardi, B., Puccini, P., . . . Imbimbo, B. P. (2004). High throughput screening of β-amyloid secretion inhibitors using homogenous time-resolved fluorescence. In Combinatorial Chemistry and High Throughput Screening Vol. 7 (pp. 745-756). PA, Philadelphia: BENTHAM SCIENCE PUBL LTD.
DOI Scopus5 WoS4 Europe PMC2

Connect With Me

External Profiles

Other Links